Insider Selling: Natera, Inc. (NASDAQ:NTRA) Director Sells 2,212 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $158.53, for a total value of $350,668.36. Following the sale, the director now directly owns 19,386 shares in the company, valued at approximately $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Natera Stock Performance

Shares of NTRA stock traded down $5.05 on Friday, reaching $146.06. The stock had a trading volume of 2,242,126 shares, compared to its average volume of 1,338,689. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average is $127.38 and its two-hundred day moving average is $115.46. The firm has a market capitalization of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53. Natera, Inc. has a 12 month low of $52.01 and a 12 month high of $167.79.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) EPS. On average, research analysts expect that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC lifted its position in Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after acquiring an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock worth $6,810,000 after purchasing an additional 9,781 shares during the period. Natixis bought a new position in shares of Natera during the first quarter worth approximately $758,000. Chartwell Investment Partners LLC increased its holdings in shares of Natera by 37.9% during the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Finally, Baader Bank Aktiengesellschaft bought a new position in shares of Natera during the second quarter worth approximately $478,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. The Goldman Sachs Group raised their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Piper Sandler restated an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Leerink Partners lifted their target price on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday. Finally, Craig Hallum boosted their price target on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $137.65.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.